Team discovers nearly universal T cell immunity against a variety of bacteria.

Published Date: 26 Apr 2023

Normally, T cells of the immune system react to a particular characteristic (antigen) of a microbe to produce protective immunity. A group of scientists from different countries have found this, as noted in the journal Immunity.

Read Full News

Latest News

Potential cancer outcome differences among psoriasis biologics found

Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern suggesting" a lower five-year risk of any first cancer (excluding non-melanoma skin cancer) with ...

Promising new drug combination for melanoma patients resistant to treatment

Melanoma is the most common form of skin cancer, but for patients with advanced melanoma who no longer respond to standard immunotherapy, treatment options are painfully limited. Vanderbilt researchers led by Professor Emerita ...

Breastfeeding linked to lasting immune protection against breast cancer

A team of researchers led by Peter Mac's Professor Sherene Loi has uncovered how having children and breastfeeding reduces a woman's long-term risk of breast cancer.

Localized IL-12 delivery reshapes CAR-T safety in solid tumors

An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding interleukin 12 strategy that lets CAR-T cells treat prostate cancer in mice while curbing previously ...

Improving immunotherapy responses to fight cancer with dual therapies

Promising study in dual inhibition of PD1 and macrophage migration inhibitory factor

BiTE-based immunotherapy strategy could point the way to a breakthrough for ovarian cancer patients

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and an immune checkpoint ...

Todays Updates

Study finds higher breast cancer rates in areas with more air pollution

Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more ...

AI tool identifies women at high risk of interval breast cancer

In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed ...

Discovery of breast cancer treatment resistance mechanism could lead to new hope for some

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...

Todays Updates

Study finds higher breast cancer rates in areas with more air pollution

Women living in parts of the United States with lower air quality, especially neighborhoods with heavy emissions from motor vehicles, are more likely to develop breast cancer, according to a multiyear analysis involving more ...

AI tool identifies women at high risk of interval breast cancer

In a study of more than 100,000 screening mammograms, researchers demonstrated the potential of an AI tool to help identify women at higher risk of developing interval breast cancer, which is breast cancer that is diagnosed ...

Discovery of breast cancer treatment resistance mechanism could lead to new hope for some

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class of therapeutics called antibody drug conjugates (ADCs). These treatments pair an antibody that targets ...

Latest News

Copenhagen University Hospital–Herlev and Gentofte led a nationwide registry study that the authors claim shows a "pattern suggesting" a lower five-year risk of any first cancer (excluding non-melanoma skin cancer) with ...

Melanoma is the most common form of skin cancer, but for patients with advanced melanoma who no longer respond to standard immunotherapy, treatment options are painfully limited. Vanderbilt researchers led by Professor Emerita ...

A team of researchers led by Peter Mac's Professor Sherene Loi has uncovered how having children and breastfeeding reduces a woman's long-term risk of breast cancer.

An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding interleukin 12 strategy that lets CAR-T cells treat prostate cancer in mice while curbing previously ...

Promising study in dual inhibition of PD1 and macrophage migration inhibitory factor

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and an immune checkpoint ...

News All Time

Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features ...

Zenocutuzumab shows clinical benefit in rare bile duct cancer

Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, ...

Investigational antibody-drug conjugate shows clinical benefit against previously treated small cell lung cancer

Zocilurtatug pelitecan (zoci), also known as ZL-1310, an investigational antibody-drug conjugate (ADC) that targets the protein DLL3, demonstrated both safety and capacity to induce anticancer responses in patients with extensive-stage ...

New targeted therapy shows promise for patients with advanced bladder cancer

FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs of clinical benefit in patients with advanced urothelial carcinoma, according ...

Scientists develop one-product-fits-all immunotherapy for breast cancer

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

Mosquito saliva may hold clues to fighting chikungunya inflammation

Scientists from the A*STAR Infectious Diseases Labs (A*STAR IDL) have uncovered a surprising mechanism showing how mosquito saliva can alter the human body's immune response during chikungunya virus (CHIKV) infection, contributing ...

Less than half of schoolkids at risk of food anaphylaxis in England prescribed adrenaline 'antidote'

Less than half of schoolchildren in England who are at risk of a serious and potentially life-threatening allergic reaction (anaphylaxis) to food were prescribed the antidote—an adrenaline [epinephrine] autoinjector, or ...

Recurrence-free survival longer with nivolumab than ipilimumab in melanoma: Study

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...

Decoding the T cell burst: Signature genes predict T cell expansion in cancer immunotherapy

The ability of immune cells—particularly CD8+ T cells—to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and mechanisms that drive this ...

Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma ...

Research targets treatment resistance in neuroendocrine tumors

A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented at the ...

Immune-altering drug suppresses tumor-protecting cells and enhances stomach cancer treatment

Working with an international team of collaborators, scientists at Columbia University have found a way to shift the balance of a type of white blood cell inside a stomach tumor, causing the immune system to recognize and ...

ADC improves outcomes in advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab ...

How multiple sclerosis harms a brain long before symptoms appear

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for years. But until recently, scientists didn't understand which brain cells were being targeted or ...

New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...

Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients ...

Recommended News For You

Why alarm is easing over a rise in pancreatic cancer among the young

To refute accusations that it failed to issue a cancer warning, Roundup's maker is asking lawmakers for assistance.

Tipiracil hydrochloride and trifluridine tablets are approved by the USFDA for Natco Pharma.

Pirtobrutinib Delays Progression in CLL Already Treated With a BTK Inhibitor

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

Getting ahead of head and neck cancer

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

Recommended Articles For You

Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease 

Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer 

Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer 

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Hybrid imaging test combines antibody and radioisotope for early lung cancer detection

2.

Kate Middleton Announces Major Cancer Update

3.

Legal, Recreational Marijuana Linked to Higher CUD Prevalence.

4.

The top three drugs for multiple myeloma treatment upfront are four.

5.

The most precise research tools for the deadliest blood cancer have been developed.

1.

Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review

2.

Exploring Innovative Solutions for Infantile Hemangioma Treatment

3.

Understanding Lymphedema: Symptoms, Causes, and Treatment 

4.

Navigating the Unknown: A Guide to Living With Hurthle Cell Thyroid Cancer

5.

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

2.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

3.

CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World

4.

Efficient Management of First line ALK-rearranged NSCLC - Part V

5.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot